Effectiveness of different treatment regimens in helicobacter pylori eradication: Ten-year experience of a single institution

Turkish Journal of Gastroenterology

Volumn 21, Issue 3, 2010, Pages 218-223

  Özden, Ali ^a   Seven, Gülseren ^a   Bektaş, Mehmet ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Eradication; Helicobacter pylori

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; TETRACYCLINE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; DRUG DOSE SEQUENCE; DRUG EFFICACY; ENDOSCOPIC BIOPSY; ERADICATION THERAPY; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; STOMACH BIOPSY; TREATMENT DURATION;

DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 77957680025     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: 10.4318/tjg.2010.0091     Document Type: Article

References (46)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-86.
2. Malaty HM, Graham DY. Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut 1994; 35: 742-5.
3. Us D, Hascelik G. Seroprevalence of Helicobacter pylori infection in an asymptomatic Turkish population. J Infect. 1998 Sep; 37: 148-50.
4. Seyda T, Derya C, Fusun A, et al. The relationship of Helicobacter pylori positivity with age, sex, and ABO Ǧ Rhesus blood groups in patients with gastrointestinal complaints in Turkey. Helicobacter 2007; 12: 244-50.
5. Morgner A, Lehn N, Andersen LP, et al. Helicobacter heilmannii associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 2000; 118: 821-8. (Pubitemid 30243744)
6. Dixon MF. Pathology of gastritis and peptic ulceration. In: Mobley HLT, Mendz GL, Hazell SL, eds. Helicobacter pylori: Physiology and Genetics. Washington, DC: ASM Press, 2001: 459-69.
7. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994; 330: 1267-71.
8. Wotherspoon AC. Helicobacter pylori infection and gastric lymphoma. Br Med Bull 1998; 54: 79-85.
9. Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet 1995; 345: 1591-4.
10. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology. 1996; 110: 1244-52.
11. Malfertheiner P, Mégraud F, Morain CO, et al. Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
12. Vakil N, Lanza F, Schwartz H, et al. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004; 20: 99-107. (Pubitemid 38938723)
13. Kadayifci A, Buyukhatipoglu H, Savas CM, et al. Eradication of Helicobacter pylori with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years. Clin Ther 2006; 2811: 1960-6.
14. Al-Eidan FA, McElnay JC, Scott MG, et al. Management of Helicobacter pylori eradication - the influence of structured counselling and follow-up. Br J Clin Pharmacol 2002; 53: 163-71.
15. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of H. pylori with triple therapy. Gastroenterology 1992; 102: 493-6.
16. Cirak MY, Engin D, Unal S, et al. Monitoring of Helicobacter pylori resistance to clarithromycin by real-time PCR assay in gastric biopsy specimens over a 4-year period in Turkey. Helicobacter 2007; 12: 449.
17. Graham DY, Abudayyeh S, El-Zimaity HM, et al. Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 245: 845-50.
18. Shehada S, Srugo I, Shaoul R. Failure of sequential therapy to eradicate Helicobacter pylori in previously treated subjects. Helicobacter 2007; 126: 645-7.
19. Aydin A, Oruc N, Turan I, Ozutemiz O, Tuncyurek M, Musoglu A. The modified sequential treatment regimen containing levofloxacin for Helicobacter pylori eradication in Turkey. Helicobacter. 2009; 14: 520-4.
20. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25.
21. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-81.
22. Fuccio L, Minardi ME, Zagari RM, et al. Meta-analysis: duration of first-line proton pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 147: 553-62.
23. De Francesco V, Margiotta M, Zullo A, et al. Primary clarithromycin resistance in Italy assessed on Helicobacter pylori DNA sequences by TaqMan real-time polymerase chain reaction. Aliment Pharmacol Ther 2006; 233: 429-35.
24. Özden A, Soykan İ, Çetinkaya H, et al. Kisa süreli üçlü tedavi kombinasyonlarinin Helicobacter pylori eradikasyonundaki etkisi. Turk J Gastroenterol 1998; 9 (Suppl 1): 54.
25. Osato MS, Reddy R, Reddy SG, et al. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001; 161: 1217-20.
26. Osato MS, Graham DY. Ranitidine bismuth citrate enhances clarithromycin activity against clinical isolates of H. pylori. Gastroenterology 1997; 112: A1057.
27. Goodwin CS, Marshall BJ, Blincow ED, et al. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol 1988; 41: 207-10.
28. Megraud F, Boyanova L, Lamouliatte H. Activity of lansoprazole against Helicobacter pylori. Lancet 1991; 337: 1486.
29. Axon ATR. Helicobacter pylori therapy effect on peptic ulcer disease. J Gastroenterol Hepatol 1991; 6: 131-7.
30. Megraud F. Adjuvant therapy for Helicobacter pylori eradication: role of lansoprazole shown in clinical studies. J Clin Gastroenterol 1995; 20 (Suppl 1): S24-7.
31. Megraud F, Roberts F, Williamson R. Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo. Helicobacter 2000; 5: 222-6.
32. Houben MHMG, van de Beek D, Hensen EF, et al. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999; 13: 1047-56.
33. Bago J, Halle ZB, Strinic D, et al. The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication - a randomised controlled trial. Wien Klin Wochenschr 2002; 114: 448-53. (Pubitemid 34764236)
34. Avsar E, Kaymakoglu S, Erzin Y, et al. Dispeptik hastalarda Helicobacter pylori eradikasyonunda 14 gunluk ranitidine bizmut sitrat bazli tedavi ile lansoprazol bazli uclu tedaviyi karsilastiran cok merkezli, randomize, prospektif bir calisma. Turk J Gastroenterol 2004; 15 (Suppl 1): 57.
35. Hatemi I, Goksel S, Bal K, et al. Helicobacter pylori eradikasyonunda 14 gunluk ranitidin bizmut sitrat, amoksisilin, klaritromisin kombinasyonunun etkinligi. Turk J Gastroenterol 2004; 15 (Suppl 1): 148.
36. Alkim H, Iscan M. Helicobacter pylori eradikasyonunda ranitidine bizmut sitratli ve proton pompa inhibitorlu kombinasyonlarinin etkinliginin karsilastirilmasi. Turk J Gastroenterol 2003; 14 (Suppl 1): 155.
37. Cinar K, Soykan I, Ozden A. The effect of Helicobacter pylori eradication in patients with functional dyspepsia: assessment of different diagnostic tests. Turk J Gastroenterol 2004; 15: 159-63. (Pubitemid 46567803)
38. Aydin A, Onder GF, Akarca US, et al. The efficacy of two-week therapy with ranitidine bismuth citrate, amoxicillin and clarithromycin on Helicobacter pylori eradication in clarithromycin-resistant and -sensitive cases. Turk J Gastroenterol 2005; 16: 203-6.
39. Cutler AF, Schubert TT. Patient factors affecting H. pylori eradication with triple therapy. Am J Gastroenterol 1993; 88: 505-9.
40. De Francesco V, Margiotta M, Zullo A, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006; 144: 94-100.
41. Uygun A, Kadayifci A, Yesilova Z, et al. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia. Clin Ther 2008; 303: 528-34.
42. Sezgin O, Altintaş E, Nayir E, et al. A pilot study evaluating sequential administration of a PPI-amoxicillin followed by a PPI-metronidazole-tetracycline in Turkey. Helicobacter 2007; 126: 629-32. (Pubitemid 350139030)
43. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007; 146: 556-63.
44. Zullo A, De Francesco V, Hassan C, et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007; 56: 1353-7.
45. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008; 148: 923-31.
46. Moayyedi P. Sequential regimens for Helicobacter pylori eradication. Lancet 2007; 370: 1010-2.